MARKET

ANIX

ANIX

Anixa Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.270
-0.080
-2.39%
After Hours: 3.300 +0.03 +0.92% 19:52 05/20 EDT
OPEN
3.340
PREV CLOSE
3.350
HIGH
3.430
LOW
3.160
VOLUME
47.39K
TURNOVER
0
52 WEEK HIGH
5.87
52 WEEK LOW
2.300
MARKET CAP
98.60M
P/E (TTM)
-6.7187
1D
5D
1M
3M
1Y
5Y
Anixa Biosciences (NASDAQ:ANIX) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 3d ago
Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright Global Investment Conference being held ...
PR Newswire · 05/05 12:30
Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Zacks · 05/02 13:40
70 Biggest Movers From Friday
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners.
Benzinga · 05/02 09:46
ANIX and CPS among mid-day movers
Gainers: GTY Technology Holdings (GTYH) +114%. Vaxxinity (VAXX) +57%. Zymeworks (ZYME) +35%. Redbox Entertainment (RDBX) +33%. Finch Therapeutics Group (FNCH) +29%. Opiant Pharmaceuticals (OPNT) +29%. Puyi (PUYI) +27%. Cyngn (CYN)
Seekingalpha · 04/29 16:48
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its breast cancer vaccine trial at the American Society of Cli...
PR Newswire · 04/28 12:30
3 Stocks Under $3 Insiders Are Aggressively Buying
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in p...
Benzinga · 04/25 11:59
BRIEF-Anixa Biosciences Says Promoted Current Chief Operating Officer And CFO, To President Effective Immediately
reuters.com · 04/15 17:23
More
No Data
Learn about the latest financial forecast of ANIX. Analyze the recent business situations of Anixa Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ANIX stock price target is 11.00 with a high estimate of 11.00 and a low estimate of 11.00.
High11.00
Average11.00
Low11.00
Current 3.270
EPS
Actual
Estimate
-0.11-0.08-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 47
Institutional Holdings: 3.46M
% Owned: 11.49%
Shares Outstanding: 30.15M
TypeInstitutionsShares
Increased
9
195.64K
New
10
147.63K
Decreased
10
63.69K
Sold Out
3
19.09K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Chairman/Chief Executive Officer/Director
Amit Kumar
President/Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Michael Catelani
Lead Director/Independent Director
Lewis Titterton
Independent Director
Arnold Baskies
Independent Director
Emily Gottschalk
No Data
No Data
About ANIX
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on oncology and infectious disease. The Company is developing chimeric endocrine receptor T-cell technology, a chimeric antigen receptor T-cell (CAR-T) technology focused on treating ovarian cancer, and anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. It is also developing vaccine against triple negative breast cancer (TNBC), the lethal form of breast cancer, and a vaccine against ovarian cancer. Its subsidiary Certainty Therapeutics, Inc. (Certainty), is developing immuno-therapy drugs against cancer.

Webull offers kinds of Anixa Biosciences Inc stock information, including NASDAQ:ANIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIX stock methods without spending real money on the virtual paper trading platform.